Diabetes Mellitus Clinical Trial
Official title:
Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?
This is a cross-sectional study that aims to assess the sensitivity and specificity of using
HbA1c as a diagnostic test for detecting the presence of diabetes mellitus (DM) when
compared to the use of oral glucose tolerance test (OGTT) among Hong Kong Chinese adult who
have impaired fasting glucose (IFG).
The investigators will recruit around 1000 non-diabetic adult participants who have impaired
fasting glucose (i.e. fasting glucose level between 5.6 to 6.9mmol/L) AND without symptoms
of hyperglycaemia to undergo both HbA1c test and oral glucose tolerance test after obtaining
their informed consent. A diagnosis of DM is confirmed when both the fasting glucose level
and 2-hour-post challenge plasma glucose level fall into diabetic range (i.e. fasting
glucose level ≥7.0mmol/L and 2-hour-post challenge plasma glucose level ≥11.1mmol/L) after a
standard 75g OGTT. Participants with only 1 plasma glucose value within the diabetic range
will be invited to repeat an oral glucose tolerance test for confirmation of their diagnosis
as recommended by American Diabetes Association and World Health Organization. Demographic
data of the participants including age, gender, smoking status, medical history, diet and
activity level will be collected. Lipid profile, blood pressure, waist circumference and
body mass index will be checked and the total cardiovascular risk in 10 years will be
calculated for each participant using the Joint British Societies 2005 and Framingham 2008
equations to evaluate the baseline cardiovascular risk of the participants.
These data will be analyzed using SPSS. The primary outcomes are the sensitivity and
specificity of HbA1c in detecting diabetes mellitus diagnosed by oral glucose tolerance test
(the gold standard). A receiver operating characteristic (ROC) curve will be obtained by
plotting sensitivity against (1-specificity) for each cutoff value for identification of an
optimal cutoff point. Diagnostic accuracy will be assessed by the area under the curve
(AUC). The differences in characteristics among participants diagnosed to have diabetes
mellitus by oral glucose tolerance test or HbA1c will be compared using independent t-test
or χ2 test for comparison between the 2 groups.
Objectives:
1. To calculate the sensitivity and specificity of HbA1c, using different cut-off values
compared to the use of OGTT as the gold standard in the diagnosis of the presence of DM
among Chinese adult patients with IFG
2. To identify the optimal cut-off value of HbA1c for diagnosing DM among the studied
population
3. To compare the prevalence of DM among Hong Kong Chinese non-diabetic adult patients
with IFG using OGTT and/or HbA1c criteria as recommended by the 2010 ADA for the
diagnosis of DM
4. To compare the characteristics (i.e. demographics, presence of risk factors for DM and
cardiovascular risk) of Hong Kong Chinese patients who are diagnosed to have DM by OGTT
criterion alone, HbA1c criterion alone, or both criteria
Hypotheses:
1. The prevalence of DM is higher among Chinese adult patients with IFG compared to the
general population of Hong Kong. The figure was estimated to be as much as 25% from
clinical observation. The overall prevalence of DM would be even higher if both OGTT
and HbA1c criteria are used.
2. The use of HbA1c, with the cut-off threshold of ≥ 6.5% recommended by the 2010 ADA
criteria for the diagnosis of DM, will pick up at least 70% of the diabetes cases
identified by OGTT among this high risk group, which is superior to its use among the
Chinese general population.
3. The sensitivity of using HbA1c ≥ 6.5% for the diagnosis of DM among this high risk
group is superior to the use of FG ≥ 7.0mmol/L.
4. The optimal cut-off threshold of HbA1c in diagnosing DM for this high risk group may
not be 6.5% but lower.
5. A subset of patients with impaired glucose regulation (IFG +/- IGT) will be identified
as diabetic according to the HbA1c criterion alone. This group of patient may have a
different cardiovascular risk profile compared to the group of patients who are
diagnosed to have DM according to plasma glucose criteria alone.
Methods:
Research Design:
This is a cross-sectional diagnostic test study to be carried out at various general
out-patient clinics (GOPCs) across Hong Kong.
Target population and Sampling method:
Around 1000 Chinese adult subjects who are classified to have IFG will be recruited from
various GOPCs from the Hong Kong West Cluster and New Territories East Cluster. Convenience
sampling will be employed.
Sample Size Calculation In this diagnostic test study, the sample size calculation was
considered using the disease prevalence and test characteristics represented by the
sensitivity and specificity of HbA1c to diagnose DM. The use of HbA1c is assumed to have an
expected sensitivity and specificity of 80%, an approximate estimate according to previous
studies, compared to OGTT for the diagnosis of DM among subjects with IFG and/or IGT. With
an estimated prevalence of DM of 25% in the high risk Chinese population in Hong Kong based
on epidemiological survey in the Chinese population with similar risk profiles, a sample of
204 subjects with DM and 612 subjects without DM will be recruited to obtain the lower limit
of the 95% confidence interval greater than 0.7 with a probability of 0.9530. A sample of
816 will be required. To account for 20% attrition rate, a total sample of 1020 will be
required, with 255 subjects with DM and 765 subjects without DM.
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |